Sera prognostics CIO sells $16,115 in company stock

Published 10/03/2025, 22:30
Sera prognostics CIO sells $16,115 in company stock

Harrison Robert Gardner, the Chief Information Officer of Sera Prognostics , Inc. (NASDAQ:SERA), recently sold 3,874 shares of the company’s Class A Common Stock. The company, currently valued at $140.5 million, has seen its stock decline by about 47% year-to-date according to InvestingPro data. The shares were sold at a weighted average price of $4.16, resulting in a total transaction value of $16,115. This sale was executed on March 7, 2025, as part of a pre-established Rule 10b5-1 trading plan adopted by Gardner in May 2024. Following this transaction, Gardner retains 121,757 shares of Sera Prognostics. With the company’s next earnings report scheduled for March 19, 2025, InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report to better understand the company’s financial position and market outlook.

In other recent news, Sera Prognostics has terminated its "at-the-market" offering prospectus supplement, as noted in a recent SEC filing. The company had initially planned to sell up to $50 million of its Class A common stock, but no shares were sold under this arrangement. Despite halting this offering, Sera Prognostics retains the option to initiate a new offering after filing a new prospectus. In a separate development, Sera Prognostics has launched a public offering of its Class A common stock and pre-funded warrants, with proceeds intended to expand U.S. operations, prepare for EU growth, and support FDA approval efforts for its PreTRM test. The offering is being managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets, and is subject to market conditions. Additionally, the company has disclosed that the Society for Maternal Fetal Medicine has published an abstract with topline results from the PRIME study, focusing on improving neonatal outcomes. These results will be discussed in detail at an upcoming presentation at the SMFM 2025 Pregnancy Meeting, followed by a conference call and webcast hosted by Sera Prognostics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.